Literature DB >> 6749280

Prolonged intermittent adjuvant chemotherapy with CCNU and hydroxyurea after resection of carcinoma of the lung.

T W Shields, G A Higgins, E W Humphrey, M J Matthews, R J Keehn.   

Abstract

Eight hundred sixty-five patients with a microscopically curative resection for carcinoma of the lung were accepted for study, none of whom were excluded from analysis. Adjuvant therapy was randomly assigned about the tenth to 14th postoperative day; 432 patients (treated) were to receive CCNU and hydroxyurea for one year, while 433 patients (controls) were to receive no adjuvant therapy. Toxic reactions to therapy were reported, but only 1% were severe enough to require stopping therapy. No evidence of improved survival or delayed recurrence of disease was seen in treated patients as a whole or when examined by cell type and by postsurgical TNM category. On the contrary, survival beyond the second year of follow-up may have been impaired by the drugs when administered to patients without evidence of tumor spread to the lymph nodes.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6749280     DOI: 10.1002/1097-0142(19821101)50:9<1713::aid-cncr2820500910>3.0.co;2-b

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

Review 1.  Neoadjuvant chemotherapy in stage IIIa non-small cell lung cancer.

Authors:  R Milroy; F Macbeth
Journal:  Thorax       Date:  1995-09       Impact factor: 9.139

Review 2.  Postoperative chemotherapy for resected non-small-cell lung cancer.

Authors:  M Crump
Journal:  World J Surg       Date:  1993 Nov-Dec       Impact factor: 3.352

Review 3.  Is the use of chemotherapy justified in non-small-cell lung cancer?

Authors:  P Kelly; L Clancy
Journal:  Drugs Aging       Date:  1994-01       Impact factor: 3.923

4.  Immunohistochemical evidence that P-glycoprotein in non-small cell lung cancers is associated with shorter survival.

Authors:  H Yokoyama; T Ishida; K Sugio; T Inoue; K Sugimachi
Journal:  Surg Today       Date:  1999       Impact factor: 2.549

Review 5.  Lung cancer: a review of current therapeutic modalities.

Authors:  A B Sandler; A C Buzaid
Journal:  Lung       Date:  1992       Impact factor: 2.584

6.  Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group.

Authors: 
Journal:  BMJ       Date:  1995-10-07

Review 7.  Chemotherapy of non-small cell lung cancer.

Authors:  C J Williams
Journal:  Br J Cancer       Date:  1989-07       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.